Drug delivery systems and methods for treatment of bladder cancer
Methods, devices, and medicaments that include oxaliplatin are provided for use in the treatment of bladder cancer by locally administering oxaliplatin into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue. The oxaliplatin may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the oxaliplatin into the urine in the bladder over an extended period of hours or days.
1. A method of treatment of bladder cancer comprising:
locally administering oxaliplatin into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue
wherein the locally administering is continuous over a period of at least one day.
2. The method of claim 1 , wherein the locally administering into the patient's bladder is at a mean average amount of from 1 mg to about 100 mg oxaliplatin per day for 1 day to 14 days.
3. The method of claim 1 , wherein the locally administering into the patient's bladder is at a mean average amount of from 1 mg to about 100 mg oxaliplatin per day for up to 7 days.
4. The method of claim 1 , wherein the oxaliplatin is delivered into the bladder from an intravesical drug delivery device which continuously releases the oxaliplatin into the urine in the bladder over a sustained period.
5. The method of claim 4 , wherein the intravesical drug delivery device continuously releases the oxaliplatin into the urine in the bladder over a period of 1 day to 14 days.
6. The method of claim 4 , wherein the intravesical drug delivery device comprises a housing which contains and controllably releases the oxaliplatin and which is elastically deformable between a retention shape configured to retain the device in a patient's bladder and a deployment shape for passage of the device through the patient's urethra.
7. The method of claim 6 , wherein the oxaliplatin contained in the housing is in a non-liquid form.
8. The method of claim 7 , wherein the non-liquid form is selected from the group consisting of tablets, granules, semisolids, capsules, and combinations thereof.
9. The method of claim 1 , further comprising administering at least a second therapeutic agent to the patient.
10. The method of claim 9 , wherein the second therapeutic agent is administered intravesically.
11. The method of claim 9 , wherein the second therapeutic agent comprises gemcitabine or another cytotoxic agent; an analgesic agent; an anti-inflammatory agent; or a combination thereof.
12. The method of claim 1 , wherein the locally administering into the patient's bladder is continuous over a 72-hour period at a mean average amount of from about 6.3 to about 6.5 mg/kg over the period.
13. A method of administering oxaliplatin to a patient in need of treatment of bladder cancer, the method comprising:
locally administering oxaliplatin into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue,
wherein the oxaliplatin is administered into the bladder from an intravesical drug delivery device which continuously releases the oxaliplatin into the urine in the bladder over a sustained period of at least one day.
14. The method of claim 13 , wherein the intravesical drug delivery device continuously releases the oxaliplatin into the urine in the bladder at a mean average amount of between 1 mg and 100 mg oxaliplatin per day.
15. The method of claim 13 , wherein the intravesical drug delivery device continuously releases the oxaliplatin into the urine in the bladder over a period of 1 day to 14 days.
16. A method of administering oxaliplatin to a patient in need of treatment of bladder cancer, the method comprising:
locally continuously administering oxaliplatin into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue,
wherein the oxaliplatin is administered into the bladder from an intravesical drug delivery device which continuously releases the oxaliplatin into the urine in the bladder over a period from 7 days to 14 days.
17. The method of claim 16 , wherein the oxaliplatin is released at a mean average amount of from 1 mg to 100 mg per day over the period.